- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
670
Companies which are more than 50% undervalued based on analyst price target.
670 companies
Erasca
Market Cap: US$419.8m
A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
ERAS
US$1.61
7D
2.5%
1Y
-43.7%
Medigen Vaccine Biologics
Market Cap: NT$12.8b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$38.85
7D
0%
1Y
-18.4%
Cullinan Therapeutics
Market Cap: US$408.2m
A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
CGEM
US$6.99
7D
-7.3%
1Y
-61.1%
Emergent BioSolutions
Market Cap: US$407.1m
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
EBS
US$7.58
7D
-8.7%
1Y
0.8%
Nanobiotix
Market Cap: €347.1m
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€7.20
7D
-8.3%
1Y
61.7%
BINEX
Market Cap: ₩561.5b
Operates as a pharmaceutical company in South Korea.
A053030
₩17,630.00
7D
9.4%
1Y
-15.2%
Aura Biosciences
Market Cap: US$398.8m
A clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
AURA
US$6.48
7D
3.5%
1Y
-16.7%
Astria Therapeutics
Market Cap: US$395.0m
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
ATXS
US$7.52
7D
21.7%
1Y
-32.4%
Lexicon Pharmaceuticals
Market Cap: US$388.8m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
LXRX
US$1.09
7D
-0.9%
1Y
-32.3%
Autolus Therapeutics
Market Cap: US$385.9m
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
AUTL
US$1.46
7D
-2.7%
1Y
-63.5%
ADC Therapeutics
Market Cap: US$382.5m
Provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADCT
US$3.54
7D
15.3%
1Y
31.1%
PureTech Health
Market Cap: UK£282.3m
Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
PRTC
UK£1.17
7D
-5.3%
1Y
-21.3%
Pacific Biosciences of California
Market Cap: US$372.5m
Designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
PACB
US$1.27
7D
-3.1%
1Y
-19.6%
Clinuvel Pharmaceuticals
Market Cap: AU$565.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$11.28
7D
5.9%
1Y
-23.4%
Benitec Biopharma
Market Cap: US$367.5m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$13.91
7D
5.1%
1Y
54.2%
Assembly Biosciences
Market Cap: US$362.7m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$23.82
7D
-3.6%
1Y
40.2%
Absci
Market Cap: US$358.9m
Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
ABSI
US$2.46
7D
2.9%
1Y
-38.8%
Abeona Therapeutics
Market Cap: US$351.8m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$6.89
7D
0.9%
1Y
24.1%
Rocket Pharmaceuticals
Market Cap: US$348.5m
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
RCKT
US$3.28
7D
0%
1Y
-82.3%
CytomX Therapeutics
Market Cap: US$346.3m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$2.28
7D
11.8%
1Y
90.0%
Larimar Therapeutics
Market Cap: US$331.2m
A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
LRMR
US$3.94
7D
8.8%
1Y
-51.1%
Aldeyra Therapeutics
Market Cap: US$331.2m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.56
7D
-4.8%
1Y
-9.3%
Tectonic Therapeutic
Market Cap: US$323.2m
A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs).
TECX
US$16.80
7D
-34.2%
1Y
-8.5%
Ocugen
Market Cap: US$321.7m
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
OCGN
US$1.03
7D
1.0%
1Y
-9.6%
Altimmune
Market Cap: US$314.2m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$3.78
7D
-1.3%
1Y
-39.0%
4D Molecular Therapeutics
Market Cap: US$308.7m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$7.27
7D
18.0%
1Y
-51.8%
Contineum Therapeutics
Market Cap: US$308.2m
A clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States.
CTNM
US$11.50
7D
10.0%
1Y
-30.9%
Foghorn Therapeutics
Market Cap: US$304.7m
A clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
FHTX
US$5.77
7D
14.0%
1Y
-23.4%
Monte Rosa Therapeutics
Market Cap: US$303.2m
A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
GLUE
US$4.94
7D
2.9%
1Y
-13.2%
Vicore Pharma Holding
Market Cap: SEK 2.8b
A clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden.
VICO
SEK 12.10
7D
3.8%
1Y
-20.5%
scPharmaceuticals
Market Cap: US$299.5m
A pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care.
SCPH
US$5.57
7D
1.3%
1Y
9.0%
Faron Pharmaceuticals Oy
Market Cap: UK£221.1m
Operates as a clinical stage drug discovery and development company.
FARN
UK£1.98
7D
-1.3%
1Y
-11.8%
Dong-A ST
Market Cap: ₩408.5b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩44,600.00
7D
0.7%
1Y
-36.2%
TerrAscend
Market Cap: CA$399.3m
TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States.
TSND
CA$1.19
7D
-24.2%
1Y
-23.2%
Tvardi Therapeutics
Market Cap: US$285.4m
A clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.
TVRD
US$31.11
7D
4.0%
1Y
n/a
Omeros
Market Cap: US$284.5m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
OMER
US$4.17
7D
0.2%
1Y
14.6%